VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

ALVAC-BTV-VP2/VP5
Vaccine Information
  • Vaccine Name: ALVAC-BTV-VP2/VP5
  • Target Pathogen: Bluetongue virus
  • Target Disease: Bluetongue disesase
  • Vaccine Ontology ID: VO_0004726
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector: ALVAC vaccine vector
  • Preparation: A recombinant canarypox virus vector was used to co-express genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus (Boone et al., 2007).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Sheep Response

  • Vaccine Immune Response Type: VO_0000287
  • Challenge Protocol: The field strain of BTV-17 was used for challenging (Boone et al., 2007).
  • Efficacy: The sheep vaccinated with the recombinant canarypox virus vectored vaccine were resistant to challenge with a field strain of BTV-17 (Boone et al., 2007).
References
Boone et al., 2007: Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, He L, Nordgren R, Monaco F, Savini G, Gardner IA, Maclachlan NJ. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine. 2007; 25(4); 672-678. [PubMed: 17059856].